Linette Ruston

1.0k total citations
14 papers, 481 citations indexed

About

Linette Ruston is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Linette Ruston has authored 14 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Genetics and 3 papers in Oncology. Recurrent topics in Linette Ruston's work include PI3K/AKT/mTOR signaling in cancer (4 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Analytical Chemistry and Chromatography (2 papers). Linette Ruston is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (4 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Analytical Chemistry and Chromatography (2 papers). Linette Ruston collaborates with scholars based in United Kingdom, France and United States. Linette Ruston's co-authors include J. Matthew Wood, Philip A. MacFaul, Nicola Colclough, Andrew G. Leach, David A. Cosgrove, Huw Jones, Peter W. Kenny, Brian K. Law, Martin Pass and Kurt G. Pike and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and European Journal of Pharmaceutical Sciences.

In The Last Decade

Linette Ruston

13 papers receiving 465 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Linette Ruston United Kingdom	8	290	143	82	66	43	14	481
Friederike Stoll Germany	9	274 0.9×	130 0.9×	66 0.8×	39 0.6×	27 0.6×	20	531
Tonika Bohnert United States	9	228 0.8×	77 0.5×	94 1.1×	138 2.1×	51 1.2×	9	558
Laura Maccari Italy	16	337 1.2×	117 0.8×	225 2.7×	119 1.8×	53 1.2×	24	662
Ola Fjellström Sweden	20	550 1.9×	83 0.6×	85 1.0×	60 0.9×	51 1.2×	40	854
Lance Goulet United States	11	379 1.3×	54 0.4×	58 0.7×	81 1.2×	23 0.5×	14	639
Xin Ku China	11	409 1.4×	120 0.8×	262 3.2×	144 2.2×	61 1.4×	25	722
Jacquelyn Klug‐McLeod United States	8	219 0.8×	190 1.3×	60 0.7×	35 0.5×	27 0.6×	11	397
Huabei Zhang China	17	325 1.1×	178 1.2×	250 3.0×	131 2.0×	72 1.7×	73	766
E. De Moliner Italy	7	432 1.5×	105 0.7×	107 1.3×	101 1.5×	22 0.5×	7	619
Suxin Zheng China	15	378 1.3×	144 1.0×	122 1.5×	37 0.6×	96 2.2×	17	556

Countries citing papers authored by Linette Ruston

Since Specialization

Citations

This map shows the geographic impact of Linette Ruston's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Linette Ruston with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Linette Ruston more than expected).

Fields of papers citing papers by Linette Ruston

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Linette Ruston. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Linette Ruston. The network helps show where Linette Ruston may publish in the future.

Co-authorship network of co-authors of Linette Ruston

This figure shows the co-authorship network connecting the top 25 collaborators of Linette Ruston. A scholar is included among the top collaborators of Linette Ruston based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Linette Ruston. Linette Ruston is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Warren, W. G., Ana David-Pereira, Daniel H. Cohn, et al.. (2024). Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral Neuropathy. Journal of Pain. 25(7). 104470–104470. 13 indexed citations

Clack, Glen, Christopher M. Moore, Linette Ruston, et al.. (2024). A Phase 1 Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enteric-Coated Stabilized Sulforaphane (SFX-01) in Male Participants. Advances in Therapy. 42(1). 216–232. 1 indexed citations

Gajjar, Parmesh, et al.. (2022). Determining bioequivalence possibilities of long acting injectables through population PK modelling. European Journal of Pharmaceutical Sciences. 179. 106296–106296. 9 indexed citations

Barlaam, Bernard, Sabina Cosulich, Martina Fitzek, et al.. (2017). Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors. Bioorganic & Medicinal Chemistry Letters. 27(13). 3030–3035. 5 indexed citations

Kettle, Jason G., Qibin Su, Neil P. Grimster, et al.. (2017). Abstract 979: Discovery of the JAK1 selective kinase inhibitor AZD4205. Cancer Research. 77(13_Supplement). 979–979. 5 indexed citations

Klein, Stéphanie, Danielle M. Greenawalt, Dawn Trueman, et al.. (2015). Abstract 5146: Establishment of an orthotopic bladder cancer model to evaluate continuous intravesical delivery of small molecule inhibitors in the nude rat. Cancer Research. 75(15_Supplement). 5146–5146. 1 indexed citations

Barlaam, Bernard, Sabina Cosulich, Martina Fitzek, et al.. (2015). Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold. Bioorganic & Medicinal Chemistry Letters. 25(13). 2679–2685. 7 indexed citations

Barlaam, Bernard, Sabina Cosulich, Bénédicte Delouvrié, et al.. (2015). Abstract 2830: Discovery of AZD8835, a potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of PIK3CA-dependent cancers. Cancer Research. 75(15_Supplement). 2830–2830.

Pike, Kurt G., Jeff Morris, Linette Ruston, et al.. (2015). Discovery of AZD3147: A Potent, Selective Dual Inhibitor of mTORC1 and mTORC2. Journal of Medicinal Chemistry. 58(5). 2326–2349. 25 indexed citations

10.

Colclough, Nicola, Linette Ruston, J. Matthew Wood, & Philip A. MacFaul. (2014). Species differences in drug plasma protein binding. MedChemComm. 5(7). 963–967. 50 indexed citations

11.

Pike, Kurt G., Karine Malagu, Marc Hummersone, et al.. (2013). Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014. Bioorganic & Medicinal Chemistry Letters. 23(5). 1212–1216. 166 indexed citations

12.

Thomas, Andrew P., Maria‐Elena Theoclitou, David Buttar, et al.. (2012). Abstract 3912: The discovery of AZD4547: An orally bioavailable, potent and selective N-(5-Pyrazolyl)benzamide FGFR1-3 inhibitor. Cancer Research. 72(8_Supplement). 3912–3912. 1 indexed citations

13.

MacFaul, Philip A., Linette Ruston, & J. Matthew Wood. (2010). Activation energies for the decomposition of pharmaceuticals and their application to predicting hydrolytic stability in drug discovery. MedChemComm. 2(2). 140–142. 18 indexed citations

14.

Leach, Andrew G., Huw Jones, David A. Cosgrove, et al.. (2006). Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties; a Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure. Journal of Medicinal Chemistry. 49(23). 6672–6682. 180 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact